Metavert

Metavert is an experimental small molecule drug developed to treat pancreatic cancer. It is designed to prevent metastasis and enhance the effectiveness of current treatments by targeting two key proteins involved in cancer growth and spread. Specifically, Metavert inhibits both glycogen synthase kinase 3 beta (GSK3β), which promotes proliferation and resistance to apoptosis in cancer cells, and histone deacetylase (HDAC), which affects epithelial cell function. By simultaneously inhibiting these targets, Metavert reduces tumor growth and metastasis while also decreasing resistance to chemotherapy agents such as gemcitabine and enhancing the effects of radiation therapy. Preclinical studies have shown that Metavert significantly increases survival rates in mouse models of aggressive pancreatic ductal adenocarcinoma (PDAC), prevents micrometastasis, reduces markers of epithelial-to-mesenchymal transition (EMT), decreases migration of cancer cells, lowers M2 macrophage levels associated with tumor progression, but does not significantly affect fibrosis[1][3][5][7].

Brand names

Metavert

Other names

N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamideBenzamide, n-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)